免疫检查点抑制剂对癌症和乙型肝炎患者的安全性和有效性：一个中低收入国家的多中心经验

IF 2.8 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2025-10-01 Epub Date: 2025-07-06 DOI:10.1080/14737140.2025.2529290

Onur Baş, Leyla Sert, Onur Yazdan Balçık, Mert Tokatli, Nur Evşan Boyraz, Gözde Kavgaci, Taha Koray Şahin, Deniz Can Güven, Zafer Arık, Abdurrahman Işikdoğan, Mustafa Erman

{"title":"免疫检查点抑制剂对癌症和乙型肝炎患者的安全性和有效性：一个中低收入国家的多中心经验","authors":"Onur Baş, Leyla Sert, Onur Yazdan Balçık, Mert Tokatli, Nur Evşan Boyraz, Gözde Kavgaci, Taha Koray Şahin, Deniz Can Güven, Zafer Arık, Abdurrahman Işikdoğan, Mustafa Erman","doi":"10.1080/14737140.2025.2529290","DOIUrl":null,"url":null,"abstract":"Background: Immune checkpoint inhibitors (ICIs) are widely used in clinical practice. The primary objective of this study is to evaluate the safety and efficacy of ICIs in patients diagnosed with cancer who also have chronic hepatitis B virus (HBV) infection.Methods: We reviewed the charts of patients who received an ICI between 2016 and 2023 at three tertiary cancer centers. We included those who had known chronic HBV infection.Results: Of the 1352 patients screened, we identified 65 (4.8%) with concurrent hepatitis B. Of the 65 patients, 8 (12.3%) experienced irAEs (immune-related adverse events) of any grade, with 1 (1.5%) having grade 3 pneumonitis. No cases of reactivation were seen except for one patient (1.5%) with poor compliance with his antiviral drug developed hepatitis B reactivation 9 months after discontinuation of ICI.Conclusion: ICIs appear safe in patients with chronic hepatitis B, especially when antiviral treatment is given. We believe these patients should not be deprived of the potential benefits of ICIs solely because of chronic viral infection, neither in daily practice nor in clinical trials.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1213-1219"},"PeriodicalIF":2.8000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country.\",\"authors\":\"Onur Baş, Leyla Sert, Onur Yazdan Balçık, Mert Tokatli, Nur Evşan Boyraz, Gözde Kavgaci, Taha Koray Şahin, Deniz Can Güven, Zafer Arık, Abdurrahman Işikdoğan, Mustafa Erman\",\"doi\":\"10.1080/14737140.2025.2529290\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Immune checkpoint inhibitors (ICIs) are widely used in clinical practice. The primary objective of this study is to evaluate the safety and efficacy of ICIs in patients diagnosed with cancer who also have chronic hepatitis B virus (HBV) infection.Methods: We reviewed the charts of patients who received an ICI between 2016 and 2023 at three tertiary cancer centers. We included those who had known chronic HBV infection.Results: Of the 1352 patients screened, we identified 65 (4.8%) with concurrent hepatitis B. Of the 65 patients, 8 (12.3%) experienced irAEs (immune-related adverse events) of any grade, with 1 (1.5%) having grade 3 pneumonitis. No cases of reactivation were seen except for one patient (1.5%) with poor compliance with his antiviral drug developed hepatitis B reactivation 9 months after discontinuation of ICI.Conclusion: ICIs appear safe in patients with chronic hepatitis B, especially when antiviral treatment is given. We believe these patients should not be deprived of the potential benefits of ICIs solely because of chronic viral infection, neither in daily practice nor in clinical trials.\",\"PeriodicalId\":12099,\"journal\":{\"name\":\"Expert Review of Anticancer Therapy\",\"volume\":\" \",\"pages\":\"1213-1219\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Anticancer Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14737140.2025.2529290\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2529290","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：免疫检查点抑制剂（ICIs）广泛应用于临床实践。本研究的主要目的是评估ICIs在患有慢性乙型肝炎病毒（HBV）感染的癌症患者中的安全性和有效性。方法：我们回顾了2016年至2023年在三家三级癌症中心接受ICI的患者图表。我们纳入了已知慢性HBV感染的患者。结果：在筛选的1352例患者中，我们发现65例（4.8%）并发乙肝。在这65例患者中，8例（12.3%）经历了任何级别的irae（免疫相关不良事件），其中1例（1.5%）患有3级肺炎。除1例（1.5%）抗病毒药物依从性差的患者在停药9个月后出现乙型肝炎再激活外，未见再激活病例。结论：慢性乙型肝炎患者使用ICIs是安全的，特别是在给予抗病毒治疗的情况下。我们认为，无论是在日常实践中还是在临床试验中，这些患者都不应该仅仅因为慢性病毒感染而被剥夺ICIs的潜在益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country.

Background: Immune checkpoint inhibitors (ICIs) are widely used in clinical practice. The primary objective of this study is to evaluate the safety and efficacy of ICIs in patients diagnosed with cancer who also have chronic hepatitis B virus (HBV) infection.

Methods: We reviewed the charts of patients who received an ICI between 2016 and 2023 at three tertiary cancer centers. We included those who had known chronic HBV infection.

Results: Of the 1352 patients screened, we identified 65 (4.8%) with concurrent hepatitis B. Of the 65 patients, 8 (12.3%) experienced irAEs (immune-related adverse events) of any grade, with 1 (1.5%) having grade 3 pneumonitis. No cases of reactivation were seen except for one patient (1.5%) with poor compliance with his antiviral drug developed hepatitis B reactivation 9 months after discontinuation of ICI.

Conclusion: ICIs appear safe in patients with chronic hepatitis B, especially when antiviral treatment is given. We believe these patients should not be deprived of the potential benefits of ICIs solely because of chronic viral infection, neither in daily practice nor in clinical trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.